Skip to main content

New Drug Approvals 2010 - Pt. XIX Dienogest (NataziaTM)

ATC code: G03AB08 and G03FA15 (as combinations)

On May 6th 2010, the FDA approved Dienogest, as a component of the oral contraceptive drug Natazia (tradename:Natazia, tradename:Qlaira). Dienogest (research code:STS-557) is a progestin is a synthetic analog of the natural product progesterone. Dienogest is one of two active components within Natazia, the other being the 17ß-estradiol prodrug - estrogen valerate; Natazia is therefore a Combination Oral Contraceptive (or COC). Natazia is the first four-phase combined oral contraceptive marketed in the United States - the four phases refering to the differential dosing of the estrogen/progestin throughout the menstrual cycle. Each monthly pack of Natazia contains pills to be taken in a specific order: 2 dark yellow tablets each containing 3 mg estradiol valerate; then 5 medium red tablets each containing 2 mg estradiol valerate and 2 mg dienogest; then 17 light yellow tablets each containing 2 mg estradiol valerate and 3 mg dienogest; then 2 dark red tablets each containing 1 mg estradiol valerate; and finally 2 white tablets (inert/placebo).

The -gest- INN stem covers progestins, a large pharmacological class of steroid structures, including (alongside dienogest) - demegestone, desogestrel, dydrogesterone, etonogestrel, gestodene, gestonorone, gestrinone, hydroxyprogesterone, levonorgestrel, medrogestone, medroxyprogesterone,
megestrol, nomegestrol, norelgestromin, norgestimate, norgestrel, norgestrienone, progesterone, promegestone, quingestanol, and trimegestone. These are usually in the G03 ATC class (Sex hormones and modulators of the genital system) and are often dosed as combination with other steroid hormones (estrogens and/or androgens). Some members of this set are in the L02 ATC class (Endocrine therapy, Antineoplastic and immunomodulatory agents)

Dienogest is a synthetic derivative of the natural steroid progesterone, and acts via similar targets to the endogenous steroid - primarily through binding to the Progesterone Receptor (PR), specifically dienogest acts as a PR agonist, with an EC50 of 3.1 nM for human PR. Progesterone Receptor (Uniprot:P06401, ChEMBL:CHEMBL208, synonym:PGR, synonym:NR3C3) is a homodimeric nuclear hormone receptor (NHR) with the drug binding at a well defined site within the ligand-binding domain (Pfam:PF00104). The nuclear receptor family are a very significant family of drug targets, with the most pharmacologically relevant members of the family acting as ligand-regulated transcription factors. Dienogest is a 19-nortestosterone derivative, and displays some androgen-related pharmacology (in the case of dienogest, it acts as an anti-androgen, with an EC50 of 420 nM). Dienogest shows no significant glucococorticoid (GR) or mineralocorticoid (MR) activity.

There is a wealth of structural data available for the molecular target of dienogest - PR, an example structure is PDBE:3d90 which is in complex with the related progestin levonorgestrol. The ligand-binding domain structure of many nuclear receptors is known, and the ligand typically fills a central hydrophobic cavity, altering the surface topology around this ligand-dependent surface site, that then can bind various co-activators/co-repressors. There are a large set of potential co-activators/co-repressors, often expressed in a tissue-specific manner. This aspect offers the potential to pharmacologically differentiate ligands directed against NHRs - leading to the identification of clinical stage PR antagonists (USAN stem -pristone, e.g. mifepristone), selective progesterone receptor modulators (SPRMs) (USAN stem -prisnil, e.g. asoprisnil), as well as agonists that are non-steroidal agonists of PR (USAN stem -proget, e.g. tanaproget).

Dienogest (IUPAC:(17α)-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile, INCHIKEY:AZFLJNIPTRTECV-FUMNGEBKSA-N, SMILES:CC12CCC3=C4CCC(=O)C=C4CCC3C1CCC2(CC#N)O , PubChem:CID68861, Chemspider:62093); has a molecular weight of 311.42 Da, has one hydrogen bond donor, three hydrogen bond acceptors, a calculated logP of 1.8, and a topological surface area of 61.1 Å2. It is therefore completely compliant with Lipinski's rule of five. There are no ionisable centers (over a biologically relevant pH range) and therefore dienogest is neutral under physiological coniditions. The four rings of the classic steroid core are obvious in the structure, and all chiral centers are present with a defined stereochemistry. Dienogest, like all steroids, is also a very rigid molecule, with only one free rotatable bond. A feature of note in the structure is the presence of the nitrile group, in which the carbon atom is reasonably electrophilic (and therefore accessible to attack by nucleophiles) -  some drugs, e.g. saxagliptin use a nitrile as a reactive group for covalent binding to the target. However, in dienogest, the nitrile does not have a mechanistic role in target modulation. Dienogest was first synthesized in the late 1970s.

Dienogest is highly bioavailable (91%) when orally dosed, and has a half-life of 12.3 hr. Following i.v. dosing, dienogest has a volume of distribution (Vd) of 46 L, and a total Clearence of 5.1 10% of circulating dienogest is in a free form, while 90% is bound to serum albumin. In contrast to many steroid like drugs, no significant binding to the steroid carrier proteins - sex-hormone binding globulin (SHBG) and corticosteroid-binding globulin (CBG) is reported. Dienogest is extensively metabolised and cleared by CYP3A4 and other pathways responsible for endogenous steroid catabolism (leading to hydroxylation and conjugation), clearance is primarily in the form of metabolites via the renal route. This reliance on CYP3A4 for metabolism leads to multiple opportunities for drug-drug interactions with both CYP3A4 inhibitors and inducers. At the 3mg dose level used in Natazia, the daily molar dose is 9.6 µmol. The average steady-state plasma concentration (for a p.o. dose of 3 mg o.d.) of dienogest is 33.7 ng/ml (equivalent to 0.11 µM)

Dienogest has a black box warning - and should not be used in smokers over 35 - in this population the risk of cardiovascular events is increased.

The full US prescribing information (for Natazia) can be found here. The same product as Natazia, but branded as Qlaira has been available within parts of Europe since 2008 - the Summary of Product Characteristics (SPC) for Qlaira is here. An earlier product (Climodien) containing dienogest, but indicated for hormone replacement therapy (HRT), has been available within some parts of the EU since 2001. The SPC for Climodien is available here.

The license holder is Bayer Healthcare and the product website is


Popular posts from this blog

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

ChEMBL 29 Released

  We are pleased to announce the release of ChEMBL 29. This version of the database, prepared on 01/07/2021 contains: 2,703,543 compound records 2,105,464 compounds (of which 2,084,724 have mol files) 18,635,916 activities 1,383,553 assays 14,554 targets 81,544 documents Data can be downloaded from the ChEMBL FTP site: .  Please see ChEMBL_29 release notes for full details of all changes in this release: New Deposited Datasets EUbOPEN Chemogenomic Library (src_id = 55, ChEMBL Document IDs CHEMBL4649982-CHEMBL4649998): The EUbOPEN consortium is an Innovative Medicines Initiative (IMI) funded project to enable and unlock biology in the open. The aims of the project are to assemble an open access chemogenomic library comprising about 5,000 well annotated compounds covering roughly 1,000 different proteins, to synthesiz

Identifying relevant compounds in patents

  As you may know, patents can be inherently noisy documents which can make it challenging to extract drug discovery information from them, such as the key targets or compounds being claimed. There are many reasons for this, ranging from deliberate obfuscation through to the long and detailed nature of the documents. For example, a typical small molecule patent may contain extensive background information relating to the target biology and disease area, chemical synthesis information, biological assay protocols and pharmacological measurements (which may refer to endogenous substances, existing therapies, reaction intermediates, reagents and reference compounds), in addition to description of the claimed compounds themselves.  The SureChEMBL system extracts this chemical information from patent documents through recognition of chemical names, conversion of images and extraction of attached files, and allows patents to be searched for chemical structures of interest. However, the curren

Julia meets RDKit

Julia is a young programming language that is getting some traction in the scientific community. It is a dynamically typed, memory safe and high performance JIT compiled language that was designed to replace languages such as Matlab, R and Python. We've been keeping an an eye on it for a while but we were missing something... yes, RDKit! Fortunately, Greg very recently added the MinimalLib CFFI interface to the RDKit repertoire. This is nothing else than a C API that makes it very easy to call RDKit from almost any programming language. More information about the MinimalLib is available directly from the source . The existence of this MinimalLib CFFI interface meant that we no longer had an excuse to not give it a go! First, we added a BinaryBuilder recipe for building RDKit's MinimalLib into Julia's Yggdrasil repository (thanks Mosè for reviewing!). The recipe builds and automatically uploads the library to Julia's general package registry. The build currently targe

New Drug Warnings Browser

As mentioned in the announcement post of  ChEMBL 29 , a new Drug Warnings Browser has been created. This is an updated version of the entity browsers in ChEMBL ( Compounds , Targets , Activities , etc). It contains new features that will be tried out with the Drug Warnings and will be applied to the other entities gradually. The new features of the Drug Warnings Browser are described below. More visible buttons to link to other entities This functionality is already available in the old entity browsers, but the button to use it is not easily recognised. In the new version, the buttons are more visible. By using those buttons, users can see the related activities, compounds, drugs, mechanisms of action and drug indications to the drug warnings selected. The page will take users to the corresponding entity browser with the items related to the ones selected, or to all the items in the dataset if the user didn’t select any. Additionally, the process of creating the join query is no